Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748457 | 0.81 | DHPS (0.50) | MEN1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL7299720 | 0.81 | ALDH1A1 (0.46) | SMN1; SMN2MEN1KMT2AMAP4K4ALDH1A1 | |
| SCHEMBL1748489 | 0.79 | L3MBTL1 (0.46) | SMN1; SMN2MEN1KMT2ARAB9ACYP1A2 | |
| SCHEMBL12209056 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL7304206 | 0.77 | SLC6A2 (0.44) | SMN1; SMN2MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL13771462 | 0.77 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| Pyrimidine SCHEMBL628523 | 0.75 | DHPS (0.45) | MEN1KMT2AALDH1A1HPGDMAPK1 | |
| SCHEMBL11440814 | 0.75 | RAB9A (0.48) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL27423552 | 0.74 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9486976 | 0.73 | TSHR (0.56) | SMN1; SMN2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968568-B2 | [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus | HOFFMANN-LA ROCHE INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2044054-B1 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | CHRIST ANDREAS D | 2010-03-18 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7674804-B2 | Pyrimidine and quinazoline derivatives as SST5 modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-2044054-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-21 | — | — | US | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000692-A2 | PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069413-A1 | Pyrimidine and Quinazoline Derivatives | SSTR5, SSTR3, NPY5R | SMN1; SMN2 2995/4885MEN1 1238/4885KMT2A 4536/4885 |
| US-20080045550-A1 | Pyrimidine and quinazoline derivatives | SSTR5, SSTR3, NPY5R | SMN1; SMN2 2995/4885MEN1 1238/4885KMT2A 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.